Dr. Montse Olivé has been appointed chair of the ERN (European Reference Network) EURO-NMD (Neuromuscular Disorders) expert group on neuromuscular pathology, replacing Professor Bjarne UDD.
On Wednesday 20 January at 7 pm, Dr. José Julve, researcher from the Cardiovascular Risk Metabolic Basis Research Group at the Sant Pau Research Institute – IIB Sant Pau will give a talk on “The anti-obesity effect of bioactive forms of vitamin B3” at the Guinardó Civic Centre. This lecture is part of the series of free seminars offered by the Research Institute at the civic centres with the aim of showing scientific advances in biomedicine and their importance in clinical practice, diagnosis and therapy of different diseases.
El Instituto de Salud Carlos III ha hecho pública la relación definitiva de concesión, a la convocatoria de plataformas de apoyo 2020 para la que se concedan subvenciones para las Unidades de las Plataformas ISCIII de apoyo a la I + D + I en Biomedicina y Ciencias de la Salud de la Acción Estratégica en Salud 2017-2020. Hay tres proyectos del Instituto de Investigación de Sant Pau-IIB Sant Pau que han sido elegidos.
A study conducted by researchers from the CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM) at the Hospital de la Santa Creu i Sant Pau Research Institute has demonstrated the protective potential against atherosclerosis of one of the forms of vitamin B3, nicotinamide, in an animal model of massive atherosclerosis.
Drs. David Ramos-Vicente and Alex Bayés, researchers of the Research Group Molecular Physiology of Synapses of the Sant Pau Research Institute-IIB Sant Pau have recently published the article “AMPA receptor auxiliary subunit auxiliary emerged during early vertebrate evolution by neo / subfunctionalization of unrelated proteins “in the scientific journal Open Biology published by the Royal Society.
Researchers from CIBERBBN, CIBERDEM, Sant Pau Research Institute- IIB Sant Pau review the role of cholesterol-carrying lipoproteins (LDL and HDL) as important factors in the development of tumours of endocrine origin.
Dr. José M. Guerra, a doctor from the Arrhythmia Unit of the Cardiology Service of Sant Pau and head of the Clinical and Translational Cardiology Research Group of the Sant Pau Research Institute- IIB Sant Pau, will give the webinar “Cardiovascular effects of COVID19” on 16 December. This seminar forms part of the joint scientific dissemination action of the Alliance of Health Research and Innovation Institutes of Catalonia (IRISCAT), which has organised a series of webinars that will deal with different topics related to biomedical research and Covid-19.
The prestigious Journal of Biological Chemistry has recently published a review and hypothesis on SARS-CoV-2 by the researcher Pablo Fuentes Prior, coordinator of the Molecular Bases of Disease research group at the Sant Pau Research Institute -IIB Sant Pau.
The Hospital de Sant Pau has collaborated in a study of the “Health Bus” project which concludes that 71.4% of middle-aged people, between 45 and 70 years old, in Lleida with a low or medium cardiovascular risk present atheromatous arteries, i.e. fatty plaques. Of these, 20% have generalised atheromatous disease, with more than 3 atheroma plaques. This finding reaffirms the assumptions about the prevalence of subclinical, undiagnosed disease in the population with common risk factors such as occult kidney disease or diabetes.
The Medical Research Institute of the Hospital de Sant Pau – IIB Sant Pau has been awarded this year’s Catalonia Construction Prize, in the category of innovation in construction, at the 17th edition of the Catalonia Construction Awards organised by the Barcelona Association of Quantity Surveyors (CAATEEB).
The spin-off, Exheus, has received the Award for Innovative Startup led by women at the MIT Enterprise Forum Spain, an event promoted by IESE Business School – University of Navarra and Massachusetts Institute of Technology that serves as a meeting point between startups, corporations, institutions and investors. This is a good recognition of the scientific-business work being carried out and the commitment to gender equality of the entire Exheus team and the institutions involved, including the Sant Pau Research Institute-IIB Sant Pau.
The Memory Unit of the Hospital de la Santa Creu i Sant Pau and the Sant Pau Research Institute, in collaboration with the Alzheimer’s and other cognitive disorders Unit of the Hospital Clínic – Idibaps and researchers of the world consortium The Dominantly Inherited Alzheimer Network (DIAN), have managed to detect cerebral changes in healthy subjects, although without clinical symptoms, which would be indicators of the beginning of an Alzheimer’s disease.
The Research Institute of the Hospital de la Santa Creu i Sant Pau of Barcelona, following this year’s motto “research for change”, wants to show how the scientific activity of the Institute in relation to Covid-19 has adapted to the situation of world health crisis caused by the new coronavirus. The activities will be conducted by the scientists of the Sant Pau Research Institute showing how they have focused their research on Covid-19 taking advantage of its relationship with the patients, or how one area of the Research Institute has become an oncohematological hospital to safely care for immunosuppressed patients.
That is why it has organized a series of activities.
Research Night talks
For the third consecutive year, Catalonia is hosting the European Research Night event, which will take place on 27th and 28th of November. More than 50 scientific organisations from all provinces are organising talks, workshops, games, experiments and many other activities for all audiences. The Hospital de Sant Pau has organised a series of activities such as micro-talks on its research projects and curiosities about its area of expertise, and informative talks in schools. You will find the information below.
AlmirallShare, the open innovation platform of Almirall, SA (ALM), announces two new collaborations with the Research Institute Foundation of the Hospital de la Santa Creu i Sant Pau and the University of South Australia (Unisa) with the aim of finding new ways of treating skin cancer and atopic dermatitis.
Dr. José Julve, the researcher in charge of the Miguel Servet programme (Carlos III Health Institute) at the Hospital de la Santa Creu i Sant Pau Research Institute – IIB Sant Pau will give the next session of “Science Mondays” with the lecture entitled “Anti-inflammatory potential of NAD+ precursor molecules in experimental models of diabetes mellitus”. The conference will take place on Monday 30 November at 6 p.m.
Pablo Alonso Coello, head of the Clinical Epidemiology and Health Services Research Group at the Sant Pau Research Institute – IIB Sant Pau has been one of the researchers on the “Highly Cited Research” list of the world’s most influential scientists, published by Clarivate Analytics, since 2016. The list, one of the most reputable classifications among the international academic and scientific community, identifies the experts who are in the top 1% of their speciality in various areas of study.
The team of the Molecular and Therapeutic Pathology of Atherothrombotic and Ischemic Diseases “ICCC Cardiovascular Programme” research group, led by Dr. Lina Badimon, from the Sant Pau-IIB Sant Pau Research Institute, is participating in the COVIRNA project, which is coordinated by the Luxembourg Institute of Health (LIH). This is one of the 23 research projects that have been awarded within the framework of the Horizon 2020 call for Expression of Interest. The work aims to promote the development of a new diagnostic test to predict the results of Covid-19 for patients and to improve cooperation between European research institutions to strengthen the response to the pandemic.
The Unit of Resistant Schizophrenia of the Sant Pau Psychiatric Service, led by Dr. Iluminada Corripio, the Research Group in Clinical Psychiatry of the Sant Pau Research Institute – IIB Sant Pau, led by Dr. Maria J. Portella, and the Research Group on Severe Mental Disorders of FIDMAG Hermanas Hospitalarias, led by Dr. Edith Pomarol-Clotet, all attached to the Center for Biomedical Research Network in Mental Health (CIBERSAM), have published the first trial in the world on the application of the surgical technique of deep brain stimulation (DBS) in patients with treatment resistant schizophrenia, which suggests that this procedure may be beneficial in some patients who do not respond adequately to any other treatment.
Next Monday, November 23, at 6 pm, the conference will be held: “The long road to describe a new muscle disease” by Dr. Montse Olivé Plana. Dr. Olivé is a member of the Neuromuscular Diseases Research Group of the Sant Pau Research Institute – IIB Sant Pau and a specialist in the Neuromuscular Diseases Unit of the Sant Pau Hospital’s Neurology Service. This session is part of the Science Monday cycle and will be streamed.
